NCT04876755View on ClinicalTrials.gov

MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer

PHASE2UnknownINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

May 30, 2021

Primary Completion Date

September 30, 2022

Study Completion Date

February 28, 2023

Conditions
Prostate Cancer RecurrentBiochemical Recurrent Prostate Cancer
Interventions
DRUG

MBM-02

MBM-02 is an HIF-1 and HIF-2 inhibitor.

Trial Locations (1)

90292

Prostate Oncology Specialists, Marina del Rey

Sponsors
All Listed Sponsors
collaborator

Prostate Oncology Specialists

UNKNOWN

lead

Matrix Biomed, Inc.

INDUSTRY

NCT04876755 - MBM-02 (Tempol) for the Treatment of Biochemical Recurrent Prostate Cancer | Biotech Hunter | Biotech Hunter